Recombinant Cynomolgus EPHA2 Protein

來源: 發(fā)布時間:2024-04-14

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.RANTES還具有抑制某些HIV-1,HIV-2和Simian免疫缺陷病毒(SIV)的菌株的能力。Recombinant Cynomolgus EPHA2 Protein,His-Avi Tag

Recombinant Cynomolgus EPHA2 Protein,His-Avi Tag,標(biāo)準(zhǔn)物質(zhì)

SARS-CoV-2,whichcausestheglobalpandemiccoronavirusdisease2019(Covid-19),belongstoafamilyofvirusesknownascoronaviruses.TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).SeveralemergingSARS-CoV-2genomeshavebeenidentifiedincludingtheOmicron,orB.1.1.529,variant.FirstidentifiedinNovember2021inSouthAfrica,theOmicronvariantquicklybecamethepredominantSARS-CoV-2variantandisconsideredavariantofconcern(VOC).TheOmicronvariantcontains15mutationsinRBDdomainthatpotentiallyaffectviralfitnessandtransmissibility.ThemajorityofthemutationsareinvolvedinACE-2bindingandOmicronbindsACE-2withgreateraffinity,potentiallyexplainingitsincreasedtransmissibility.Severalofthesemutationsarealsoidentifiedinfacilitatingimmuneescapeandreducingneutralizationactivitytoseveralmonoclonalantibodies.Recombinant Cynomolgus CD30/TNFRSF8 Protein,His Tag凝血酶是由大小分別為31 KD和6 KD的兩條肽鏈通過二硫鍵組成的一種絲氨酸蛋白水解酶。

Recombinant Cynomolgus EPHA2 Protein,His-Avi Tag,標(biāo)準(zhǔn)物質(zhì)

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS?CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 .The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Before binding to the ACE-2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy. Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy.  

Recombinant Biotinylated Human KIR2DL1 Protein,His-Avi Tag性能參數(shù)分子別名(Synonyms)CD158A;CD158Ankat1;cl-42表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)BiotinylatedHumanKIR2DL1ProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsHis22-Arg242.[Accession|P43626]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof27.1kDa.Duetoglycosylation,theproteinmigratesto48-60kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.LAG-1與MIP-1β(ACT II同種型)相同,Lag-1趨化吸引力單核細(xì)胞,并表現(xiàn)出活性作為HIV抑制因子。

Recombinant Cynomolgus EPHA2 Protein,His-Avi Tag,標(biāo)準(zhǔn)物質(zhì)

IdeS Protease全稱免疫球蛋白G降解酶,酶活(Enzymeactivity)40U/μL酶活定義(UnitDefinition)在37℃條件下,反應(yīng)30min,剪切>95%的1μg重組單克隆IgG所需要的酶量定義為一個活性單位。儲存條件-25~-15℃保存,有效期1年。使用方法1.在消化液中加入適量IgG(加至5mg);2.在IgG樣本中加入IdeS蛋白酶(每1μgIgG加入1個單位的IdeS);3.將樣品置于37℃孵育30-60min。IdeS蛋白酶在中性pH或接近中性pH的緩沖中活性強(qiáng)。推薦反應(yīng)緩沖是50mM磷酸鈉,150mMNaCl(pH6.6),多數(shù)常見的生物緩沖也適用,比如Tris或PBS;注意:不在此pH范圍(例如乙酸鹽緩沖液)的緩沖也可能適用,但是孵育時間或酶量需要根據(jù)實(shí)際情況進(jìn)行優(yōu)化。注意事項1.IdeS不能識別切割小鼠IgG1/IgG2b,大鼠、豬、牛和山羊IgG,對小鼠IgG2a和IgG3具有中等酶切活性,酶切小鼠IgG2a和IgG3建議增加IdeS的用量(推薦用量為正常用量的5-10倍)。2.IdeS不能切割非IgG亞型的單抗分子,包括IgA、IgM、IgD和IgE。雙堿性內(nèi)切酶又稱為Kex2蛋白酶、YSCF蛋白酶,在酵母體內(nèi)Kex2蛋白酶負(fù)責(zé)加工killer toxin和α-factor的前體。Recombinant Mouse Kremen-2 Protein,His Tag

UbcH3還有兩個泛素結(jié)合位點(diǎn)UBS1(來自aa 205-215)和UBS2(來自aa 216-225),以及一個c端酸性尾部結(jié)構(gòu)域。Recombinant Cynomolgus EPHA2 Protein,His-Avi Tag

產(chǎn)品簡介凝血酶是由大小分別為31KD和6KD的兩條肽鏈通過二硫鍵組成的一種絲氨酸蛋白水解酶,可從動物血漿中利用已凝血酶原水解制得,可催化纖維蛋白原(fibrinogen)水解釋放A肽和B肽,由此形成纖維蛋白單體,單體進(jìn)一步聚合,在血小板、紅細(xì)胞和白細(xì)胞等參與下形成血凝塊,常用于診斷學(xué)中凝血化驗(yàn)、凝血因子檢測、血液或血漿的脫纖維化等;另外,由于凝血酶切割序列專一,水解效率高,因此在分子生物學(xué)、生物化學(xué)或生物工程制藥研究中也常作為工具酶用于重組融合蛋白(包含凝血酶識別位點(diǎn))的特異性斷裂。本品是從牛的血漿純化制得,具有純度高、比活高、不含有其他蛋白酶活性、滅活病毒、生產(chǎn)穩(wěn)定性好等特點(diǎn)。該酶適切割位點(diǎn):A-B-Pro-Arg-▼-X-Y(其中,A和B為疏水氨基酸,X和Y為非酸性氨基酸),常見的識別序列為:1.Leu-Val-Pro-Arg-▼-Gly-Ser。2.Gly-Arg-▼-Gly。產(chǎn)品信息規(guī)格1KU/2KURecombinant Cynomolgus EPHA2 Protein,His-Avi Tag

浦斯瑞(上海)生物醫(yī)藥有限公司匯集了大量的優(yōu)秀人才,集企業(yè)奇思,創(chuàng)經(jīng)濟(jì)奇跡,一群有夢想有朝氣的團(tuán)隊不斷在前進(jìn)的道路上開創(chuàng)新天地,繪畫新藍(lán)圖,在江蘇省等地區(qū)的化工中始終保持良好的信譽(yù),信奉著“爭取每一個客戶不容易,失去每一個用戶很簡單”的理念,市場是企業(yè)的方向,質(zhì)量是企業(yè)的生命,在公司有效方針的領(lǐng)導(dǎo)下,全體上下,團(tuán)結(jié)一致,共同進(jìn)退,**協(xié)力把各方面工作做得更好,努力開創(chuàng)工作的新局面,公司的新高度,未來浦斯瑞(上海)生物醫(yī)藥供應(yīng)和您一起奔向更美好的未來,即使現(xiàn)在有一點(diǎn)小小的成績,也不足以驕傲,過去的種種都已成為昨日我們只有總結(jié)經(jīng)驗(yàn),才能繼續(xù)上路,讓我們一起點(diǎn)燃新的希望,放飛新的夢想!